Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

Julie A. Zorn(QB3), Pavel Strop(Pfizer (United States)), Matthew L. Wheeler(Bristol-Myers Squibb (United States)), Bryant Chau(Bristol-Myers Squibb (United States)), Winston S. Thomas(Bristol-Myers Squibb (United States)), Naveen K. Neradugomma(Bristol-Myers Squibb (United States)), Gavin Dollinger(Bristol-Myers Squibb (United States)), Srikanth Kotapati(Bristol-Myers Squibb (United States)), Sean M. West(Bristol-Myers Squibb (United States)), Winse Morishige(Bristol-Myers Squibb (United States)), Sayumi Yamazoe(Bristol-Myers Squibb (Germany)), Richard Y.‐C. Huang(Bristol-Myers Squibb (United States)), Ralston M. Barnes(Bristol-Myers Squibb (Germany)), Anastasia Kosenko(Bristol-Myers Squibb (United States)), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Ian Schindler(Bristol-Myers Squibb (United States)), Jim Kaberna(Bristol-Myers Squibb (United States)), Feng Wang(Shanghai Jiao Tong University), Guodong Chen(Bristol-Myers Squibb (United States)), Kathleen Powers(Bristol-Myers Squibb (United States)), Jack Lohre(Sequoia Hospital), Arvind Rajpal(Pfizer (United States)), Marek Harris(Bristol-Myers Squibb (United States)), Yinhan Zhou(Bristol-Myers Squibb (United States)), Yu Chang(Bristol-Myers Squibb (United States)), Tim W. Sproul(Bristol-Myers Squibb (United States))

Scientific Reports

March 3, 2022

Cited by 22

|New England Journal of Medicine|2013|1.5k

|New England Journal of Medicine|2012|845

|Gut|2012|613

|Science|2002|603

|Chemistry & Biology|2013|498

Related Papers